NeoGenomics 향후 성장
Future 기준 점검 0/6
NeoGenomics은 연간 수입과 매출이 각각 57.4%와 8.5% 증가할 것으로 예상되고 EPS는 연간 56.6%만큼 증가할 것으로 예상됩니다.
핵심 정보
57.4%
이익 성장률
56.64%
EPS 성장률
| Healthcare 이익 성장 | 18.3% |
| 매출 성장률 | 8.5% |
| 향후 자기자본이익률 | n/a |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 29 Apr 2026 |
최근 향후 성장 업데이트
Recent updates
내러티브 업데이트 • May 01
NEO: Expanded Test Access And Coverage Will Support Long Term Upside
Analysts have revised their fair value estimate for NeoGenomics from $17.00 to about $23.43. This change reflects updated assumptions for long term revenue growth, profit margins, and a higher future P/E multiple.
내러티브 업데이트 • Apr 17
NEO: Medicare Test Coverage Will Support Bullish Repricing Through 2026 Guidance
Analysts have trimmed their price target on NeoGenomics from about $14.81 to roughly $14.19, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that modestly reset expectations while keeping the broader thesis intact. What's in the News PanTracer LBx received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043.
내러티브 업데이트 • Apr 03
NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026
Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).내러티브 업데이트 • Mar 19
NEO: New Medicare Coverage Will Drive Bullish Repricing Through 2026 Guidance
Analysts have kept their $14.81 price target for NeoGenomics unchanged, citing stable modeled revenue growth, profit margins, and future P/E assumptions as the basis for maintaining their view. What's in the News Medicare, through the MolDX program, granted coverage for NeoGenomics' PanTracer LBx liquid biopsy test for plasma based genomic profiling in solid tumors, expanding access for Medicare patients to a blood based comprehensive genomic profiling assay that evaluates more than 500 genes with a seven day turnaround (Key Developments).내러티브 업데이트 • Mar 05
NEO: Legal Victory And 2025–2026 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on NeoGenomics from about $14.43 to roughly $14.81, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News NeoGenomics launched RaDaR ST, a circulating tumor DNA assay for molecular residual disease that uses patient specific, tumor informed panels and whole exome sequencing to track up to 48 tumor variants with an LOD95 of 11 ppm.내러티브 업데이트 • Feb 19
NEO: Liquid Biopsy Expansion And Legal Win Will Support Long Term Upside
Analysts have kept their $17.00 price target for NeoGenomics unchanged, reflecting only small model tweaks to the discount rate, revenue growth assumptions, profit margin expectations, and future P/E that do not materially alter their overall view of the stock. What's in the News Issued earnings guidance for 2026 with expected consolidated revenue of US$793 million to US$801 million and a projected net loss of US$63 million to US$50 million.내러티브 업데이트 • Feb 05
NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data
Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.Seeking Alpha • Jan 25
NeoGenomics: Distribution Moat In Community Oncology
Summary NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration. NEO trades at a significant discount to sector peers on EV/Sales and P/S, offering a margin of safety if execution on MRD and margin expansion materializes. Read the full article on Seeking Alpha내러티브 업데이트 • Jan 22
NEO: Legal Win And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target for NeoGenomics to about US$14.43 from roughly US$13.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s long-term earnings power. What's in the News Issued preliminary unaudited guidance for the fourth quarter of 2025 with expected total revenue of about US$190 million and year over year growth of 11%, and full year 2025 revenue of about US$727 million with year over year growth of 10% (company guidance).내러티브 업데이트 • Jan 08
NEO: Future Liquid Biopsy Data Pipeline Will Support Stronger Long Term Outlook
Analysts have lifted their fair value estimate for NeoGenomics from US$14.00 to US$17.00. They cite updated assumptions around revenue growth, profit margins and future P/E that they believe better reflect the company’s outlook.내러티브 업데이트 • Dec 14
NEO: Upcoming Trial Readouts And Guidance Will Drive Bullish Repricing
Narrative Update on NeoGenomics Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook. What's in the News Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).내러티브 업데이트 • Nov 29
NEO: Upcoming Research and Earnings Guidance Will Shape Market Expectations
Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.내러티브 업데이트 • Nov 15
NEO: Upcoming Research Presentations Are Expected To Drive Solid Tumor Detection Momentum
Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.내러티브 업데이트 • Nov 01
NEO: Upcoming Research Presentations Will Accelerate Future Oncology Diagnostic Opportunities
Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.내러티브 업데이트 • Oct 18
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.내러티브 업데이트 • Aug 30
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.분석 기사 • Aug 27
Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jul 30
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • May 23
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 25% in the last thirty...
새로운 내러티브 • Mar 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.분석 기사 • Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 28% in the last thirty...Seeking Alpha • Feb 28
NeoGenomics: Decent Fundamentals, But Still Overvalued
Summary NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern. Intrinsic value calculations using the Graham's Formula and DCF model suggest the stock may not yet be done falling. I am recommending caution. Read the full article on Seeking Alpha분석 기사 • Feb 18
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Jan 14
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash
NeoGenomics, Inc. ( NASDAQ:NEO ) shares have had a horrible month, losing 29% after a relatively good period...분석 기사 • Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...분석 기사 • Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2028 | 965 | -21 | N/A | N/A | 6 |
| 12/31/2027 | 881 | -37 | N/A | 74 | 12 |
| 12/31/2026 | 800 | -58 | N/A | 39 | 12 |
| 3/31/2026 | 746 | -99 | -5 | 22 | N/A |
| 12/31/2025 | 727 | -108 | -22 | 5 | N/A |
| 9/30/2025 | 709 | -113 | -17 | 14 | N/A |
| 6/30/2025 | 689 | -104 | -19 | 14 | N/A |
| 3/31/2025 | 672 | -78 | -32 | 8 | N/A |
| 12/31/2024 | 661 | -79 | -34 | 7 | N/A |
| 9/30/2024 | 644 | -78 | -22 | 15 | N/A |
| 6/30/2024 | 628 | -79 | -30 | 0 | N/A |
| 3/31/2024 | 611 | -84 | -40 | -15 | N/A |
| 12/31/2023 | 592 | -88 | -31 | -2 | N/A |
| 9/30/2023 | 575 | -96 | -50 | -23 | N/A |
| 6/30/2023 | 552 | -115 | -64 | -34 | N/A |
| 3/31/2023 | 530 | -126 | -82 | -50 | N/A |
| 12/31/2022 | 510 | -144 | -97 | -66 | N/A |
| 9/30/2022 | 497 | -163 | -120 | -82 | N/A |
| 6/30/2022 | 489 | -147 | -119 | -74 | N/A |
| 3/31/2022 | 486 | -36 | -115 | -58 | N/A |
| 12/31/2021 | 484 | -8 | -91 | -27 | N/A |
| 9/30/2021 | 485 | 49 | -65 | -1 | N/A |
| 6/30/2021 | 489 | 72 | -49 | 7 | N/A |
| 3/31/2021 | 454 | -11 | -30 | 11 | N/A |
| 12/31/2020 | 444 | 4 | -28 | 1 | N/A |
| 9/30/2020 | 425 | -5 | -25 | -1 | N/A |
| 6/30/2020 | 405 | -5 | -6 | 17 | N/A |
| 3/31/2020 | 419 | 3 | -11 | 10 | N/A |
| 12/31/2019 | 409 | 8 | N/A | 23 | N/A |
| 9/30/2019 | 378 | 2 | N/A | 35 | N/A |
| 6/30/2019 | 343 | 2 | N/A | 25 | N/A |
| 3/31/2019 | 309 | 6 | N/A | 37 | N/A |
| 12/31/2018 | 277 | 6 | N/A | 45 | N/A |
| 9/30/2018 | 262 | 8 | N/A | 35 | N/A |
| 6/30/2018 | 252 | -1 | N/A | 34 | N/A |
| 3/31/2018 | 246 | -9 | N/A | 34 | N/A |
| 12/31/2017 | 240 | -11 | N/A | 18 | N/A |
| 9/30/2017 | 239 | -27 | N/A | 12 | N/A |
| 6/30/2017 | 241 | -26 | N/A | 14 | N/A |
| 3/31/2017 | 242 | -29 | N/A | 13 | N/A |
| 12/31/2016 | 232 | -31 | N/A | 21 | N/A |
| 9/30/2016 | 211 | -18 | N/A | 24 | N/A |
| 6/30/2016 | 175 | -12 | N/A | 17 | N/A |
| 3/31/2016 | 136 | -7 | N/A | 14 | N/A |
| 12/31/2015 | 100 | -3 | N/A | 6 | N/A |
| 9/30/2015 | 98 | 0 | N/A | 5 | N/A |
| 6/30/2015 | 96 | 0 | N/A | 6 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: NEO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 vs 시장: NEO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
고성장 수익: NEO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.
수익 대 시장: NEO 의 수익(연간 8.5%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: NEO 의 수익(연간 8.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: NEO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 03:25 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
NeoGenomics, Inc.는 25명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |